the alpha-helical, LR and C-terminal domains indicated. Critical amino acid residues and domains essential for different functions of Vpr were determined by mutational analysis.--

In the Claims:

Please cancel claims 12-27 without prejudice and amend claims 1 and 11 to read as follows:

1. (Amended) A conjugated composition comprising:

a fragment of HIV-1 Vpr comprising amino acid sequence 17-36 and/or 59-84 or a non-HIV-1 Vpr protein comprising amino acids 17-36 and/or 59-84 of HIV-1 Vpr protein conjugated to a therapeutic compound.

11. (Amended) The method of claim 7 wherein said compound is an antisense oligonucleotide.

REMARKS

Claims 1-11 are pending in the present application. Applicants have cancelled claims 12-27, which are drawn to non-elected inventions, without prejudice to their presentation in another application. Claims 1 and 11 have been amended herein, support for which can be found, for example, at page 29, lines 16-23 of the specification. No new matter has been added.

As a preliminary matter, Applicants acknowledge receipt of the "Attachment for PTO-948" outlining changes for prosecution of applications containing drawings. Formal drawings for Figures 5, 6A and 6B have been filed on date even herewith under separate cover to the Draftsperson.

The Office Action asserts that Figure 5 contains sequence disclosure and request Applicants to submit a substitute Sequence Listing. The only sequence identified in Figure 5 is the amino acid sequence of macrophage trophic clone 89.6 Vpr, which is already listed in the Sequence Listing as SEQ ID NO:4. Applicants have amended the description of Figure 5 to recite the particular sequence identifier. In addition, the description of Figure 5 has also been amended to recite the text deleted from the drawing so that Applicants can comply with the draftspersons request regarding margins. No new matter has been added. Further, no additional Sequence Listing is required.